Archives: “Clinical Trials”

Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis

https://www.coltonconsortium.org/publications/tolebrutinib-in-nonrelapsing-secondary-progressive-multiple-sclerosis/

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab

https://www.coltonconsortium.org/publications/trajectory-of-beta-cell-function-and-insulin-clearance-in-stage-2-type-1-diabetes-natural-history-and-response-to-teplizumab/

Risk of relapse of antineutrophil cytoplasmic antibody–associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids

https://www.coltonconsortium.org/publications/risk-of-relapse-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-in-a-randomized-controlled-trial-of-plasma-exchange-and-glucocorticoids/

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

https://www.coltonconsortium.org/publications/safety-and-efficacy-of-evobrutinib-in-relapsing-multiple-sclerosis-evolutionrms1-and-evolutionrms2-two-multicentre-randomised-double-blind-active-controlled-phase-3-trials/

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study

https://www.coltonconsortium.org/publications/safety-and-tolerability-of-conversion-to-siponimod-from-other-disease-modifying-therapies-in-patients-with-advancing-forms-of-relapsing-ms-results-from-the-exchange-study/

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS

https://www.coltonconsortium.org/publications/short-and-long-term-effects-of-early-versus-delayed-treatment-with-ocrelizumab-on-cerebellar-volume-loss-in-patients-with-rms-and-ppms/

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes

https://www.coltonconsortium.org/publications/teplizumab-induces-persistent-changes-in-the-antigen-specific-repertoire-in-individuals-at-risk-for-type-1-diabetes/

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

https://www.coltonconsortium.org/publications/crizanlizumab-for-retinal-vasculopathy-with-cerebral-leukoencephalopathy-in-a-phase-ii-clinical-study/

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies

https://www.coltonconsortium.org/publications/effect-of-bimekizumab-on-patient-reported-disease-impact-in-patients-with-psoriatic-arthritis-1-year-results-from-two-phase-3-studies/

Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial

https://www.coltonconsortium.org/publications/efficacy-and-safety-of-avacopan-in-patients-aged-65-years-and-older-with-anca-associated-vasculitis-a-post-hoc-analysis-of-data-from-the-advocate-trial/